Parsaclisib & Sirolimus Gel Filed In EU For Rare Diseases

Incyte’s next-generation PI3K-delta inhibitor, parsaclisib, and Nobelpharma’s topical sirolimus gel are among the latest marketing authorization applications that have been filed in the EU.

New drugs are under review for potential use in the EU • Source: Alamy

The European Medicines Agency has begun reviewing a new batch of treatments for potential pan-EU marketing authorization, including parsaclisib, a next-generation PI3K-delta inhibitor, and a topical gel formulation of the generic drug sirolimus, both of which have orphan status.

Parsaclisib, from Incyte, was filed with the EMA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)

More from Europe

More from Geography

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By 

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.